Global Relay Intelligence & Practice
All the latest news, insights, and publications from Global Relay.
Latest stories
Our regular columnist Carroll Barry-Walsh returns with some thoughts about the challenges recruiters increasingly face.
Regulator urges firms experiencing growth to consider findings and assess whether arrangements remain appropriate.
Our regular roundup of the latest news and developments from the FCA.
Sheridan joined us to discuss the status quo of cryptocurrency investigations.
Highlights
Spotlight
Steve Penry on the evolution of energy market surveillance
Related articles
Industries Feed
Podcasts
Compliance
Disciplinary decisions issued June 27 – July 3, 2026.
We explore the compatibility of defense investments with responsible investing with Alex Miller, Danesmead Advisory.
Mayr shares her story from math and economics to energy markets; and discusses the latest developments.
Case examines allegations involving AstraZeneca under the ABPI Code, underscoring the compliance controls drugmakers need to implement.
Regulation
FDA sets FY 2027 medical device user fees, updating submission and registration costs under MDUFA V and outlining small business reductions.
Two FCA consultation papers prepare for implementation of an equities CT in the UK and aim to improve accessibility and clarity of trade data.
A new study found proposed Medicare drug pricing models may rely on prices from relatively few international markets.
Centers for Medicare & Medicaid Services moves to strengthen oversight of Applied Behavior Analysis services and reduce fraud, waste, and abuse.
Technology
A NYDFS investigation following a ransomware attack uncovered an inadequate cybersecurity risk assessment.
OpenAI provided the first detailed explanation of the Hugging Face incident at the annual cybersecurity conference in Las Vegas.
Overview of EU AI Act transparency obligations under Art 50, and guidance for legal and compliance counsel.
Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
Get full access, free for a month
Stay ahead with the compliance and regulatory insight you need. Start your 28-day free trial to access all content on GRIP – no payment details required.
What’s included:
- Every new article, plus our 5,000+ archive
- Daily regulatory insight and guidance
- Exclusive interviews and in-depth analysis
- Coverage of industry-leading events and conferences
- All podcasts and videos, featuring industry experts
- The full set of Rules Navigator tools
- An ad-free experience
Energy markets in the spotlight